IS4572A - Leysnistýring á ljósopsþrengjandi og ljósopsvíkkandi lyfjum í augnvökvahólfinu. - Google Patents

Leysnistýring á ljósopsþrengjandi og ljósopsvíkkandi lyfjum í augnvökvahólfinu.

Info

Publication number
IS4572A
IS4572A IS4572A IS4572A IS4572A IS 4572 A IS4572 A IS 4572A IS 4572 A IS4572 A IS 4572A IS 4572 A IS4572 A IS 4572A IS 4572 A IS4572 A IS 4572A
Authority
IS
Iceland
Prior art keywords
opacifiers
eyelid
apertures
compartment
solvent control
Prior art date
Application number
IS4572A
Other languages
English (en)
Inventor
A. Galin Miles
C. Salamone Joseph
C. Israel Stanley
Original Assignee
A. Galin Miles
C. Salamone Joseph
C. Israel Stanley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A. Galin Miles, C. Salamone Joseph, C. Israel Stanley filed Critical A. Galin Miles
Publication of IS4572A publication Critical patent/IS4572A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS4572A 1995-04-18 1997-09-30 Leysnistýring á ljósopsþrengjandi og ljósopsvíkkandi lyfjum í augnvökvahólfinu. IS4572A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/423,703 US5612027A (en) 1995-04-18 1995-04-18 Controlled release of miotic and mydriatic drugs in the anterior chamber
PCT/US1996/005395 WO1996032951A1 (en) 1995-04-18 1996-04-18 Controlled release of miotic and mydriatic drugs in the anterior chamber

Publications (1)

Publication Number Publication Date
IS4572A true IS4572A (is) 1997-09-30

Family

ID=23679887

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4572A IS4572A (is) 1995-04-18 1997-09-30 Leysnistýring á ljósopsþrengjandi og ljósopsvíkkandi lyfjum í augnvökvahólfinu.

Country Status (26)

Country Link
US (4) US5612027A (is)
EP (1) EP0822822A4 (is)
JP (1) JP3314085B2 (is)
KR (1) KR100307685B1 (is)
CN (1) CN1181703A (is)
AP (1) AP850A (is)
AU (1) AU707013B2 (is)
BG (1) BG62598B1 (is)
BR (1) BR9608441A (is)
CA (1) CA2216417C (is)
CZ (1) CZ326497A3 (is)
DE (1) DE822822T1 (is)
EA (1) EA000790B1 (is)
EE (1) EE9700286A (is)
ES (1) ES2116950T1 (is)
GE (1) GEP20002231B (is)
HU (1) HUP9802665A3 (is)
IS (1) IS4572A (is)
MX (1) MX9708043A (is)
NO (1) NO974808L (is)
NZ (1) NZ306875A (is)
OA (1) OA10744A (is)
PL (1) PL322820A1 (is)
SK (1) SK140297A3 (is)
TR (1) TR199701192T1 (is)
WO (1) WO1996032951A1 (is)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
WO1999055304A1 (en) 1998-04-29 1999-11-04 Novartis Ag Methods and compositions for stabilizing acetylcholine compositions
DK172900B1 (da) 1998-12-18 1999-09-27 Per Julius Nielsen Præparat samt kit til brug ved intraoculære operationer
EP1165097B1 (en) 1999-02-01 2007-05-02 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and their use
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US7060297B2 (en) 2000-11-06 2006-06-13 Alcon, Inc. Carrageenan viscoelastics for ocular surgery
US20030060447A1 (en) * 2002-04-24 2003-03-27 Mutlu Karakelle Non-aspirating transitional viscoelastics for use in surgery
AU2002229434A1 (en) * 2001-01-29 2002-08-12 Bernard B. Fresco Controlled release microsphere system for administration of drug to the eye
WO2003043660A2 (en) * 2001-11-21 2003-05-30 Novartis Ag Composition for stabilizing hyaluronic acid
ES2397574T3 (es) * 2002-07-30 2013-03-08 Omeros Corporation Procedimiento y soluciones de irrigación oftalmológica
JP2004143155A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 眼科用剤
US20040167480A1 (en) * 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
DK2413894T3 (en) * 2009-04-02 2017-04-03 Allergan Inc HIGHLY FORMED HYDROGLES FOR SOFTWARE STRENGTH
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
KR102337046B1 (ko) 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US20210267885A1 (en) * 2016-05-25 2021-09-02 Singapore Health Services Ptel Ltd Atropine-containing aqueous composition
KR102472774B1 (ko) 2016-08-19 2022-11-30 오라시스 파마슈티칼스 엘티디. 안과용 약학 조성물 및 이와 관련된 용도
JP6946575B2 (ja) 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼の状態の治療のためのピロカルピン塩酸塩の使用
FR3086865B1 (fr) * 2018-10-04 2023-04-28 Matthieu Leconte Preparation ophtalmique et lentille d'orthokeratologie pour l'inhibition, la prevention et/ou la limitation de la progression de la myopie

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001388A (en) * 1973-06-14 1977-01-04 Alza Corporation Ophthalmological bioerodible drug dispensing formulation
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4303637A (en) * 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
CH666897A5 (fr) * 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5093126A (en) * 1987-09-26 1992-03-03 Alcon Laboratories, Inc. Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
US4965253A (en) * 1987-10-14 1990-10-23 University Of Florida Viscoelastic material for ophthalmic surgery
US4920104A (en) * 1988-05-16 1990-04-24 Medchem Products, Inc. Sodium hyaluronate composition
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5007913A (en) * 1989-09-19 1991-04-16 Alcon Surgical, Inc. Apparatus and method for implantation of intraocular lenses
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
SE9301422D0 (sv) 1993-04-28 1993-04-28 Kabi Pharmacia Ab Method and means for inhibiting posterior capsule opacification
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber

Also Published As

Publication number Publication date
CA2216417A1 (en) 1996-10-24
NZ306875A (en) 1999-06-29
JPH10510293A (ja) 1998-10-06
AP850A (en) 2000-06-14
BR9608441A (pt) 1999-02-17
CA2216417C (en) 2003-03-18
DE822822T1 (de) 1998-09-03
CN1181703A (zh) 1998-05-13
BG101960A (en) 1998-04-30
US5612027A (en) 1997-03-18
SK140297A3 (en) 1999-01-11
HUP9802665A3 (en) 2000-06-28
AP9701099A0 (en) 1997-10-31
NO974808D0 (no) 1997-10-17
OA10744A (en) 2002-12-11
NO974808L (no) 1997-12-15
KR19990007837A (ko) 1999-01-25
CZ326497A3 (cs) 1998-09-16
KR100307685B1 (ko) 2001-12-12
GEP20002231B (en) 2000-09-25
US5965152A (en) 1999-10-12
US5759532A (en) 1998-06-02
AU5555796A (en) 1996-11-07
EA000790B1 (ru) 2000-04-24
EP0822822A1 (en) 1998-02-11
AU707013B2 (en) 1999-07-01
PL322820A1 (en) 1998-02-16
US5766580A (en) 1998-06-16
ES2116950T1 (es) 1998-08-01
BG62598B1 (bg) 2000-03-31
JP3314085B2 (ja) 2002-08-12
EE9700286A (et) 1998-06-15
TR199701192T1 (xx) 1998-02-21
MX9708043A (es) 1998-03-31
EP0822822A4 (en) 2006-01-11
WO1996032951A1 (en) 1996-10-24
EA199700286A1 (ru) 1998-04-30
HUP9802665A2 (en) 1999-06-28

Similar Documents

Publication Publication Date Title
DE69608973D1 (de) Schalter und diesen enthaltende Schaltungsanordnung
DE69405782D1 (de) Verbinder
DE69411322D1 (de) Verbinder
DE69602426D1 (de) Elektrisch betriebener handschläger und -rührer
DE69636930D1 (de) Schaltungsplatte und Schaltungsplattenanordnung
DE69600634D1 (de) Elektrisch betriebener handschläger und -rührer
NO981282D0 (no) Calcitriolderivater og deres anvendelser
NO950174D0 (no) PLL syntetiserer og fremgangsmåte for styring av samme
DE69408554D1 (de) Verbinder
DK0906529T3 (da) Aktiveringsstift
DE69602680D1 (de) Schlauchboot
DE69413911D1 (de) Verbinder
DE69416082D1 (de) Scharniersatz
NO974058D0 (no) Fargestoff og framgangsmåte for framstilling av samme
FR2736814B1 (fr) Penderie repliable
NO943928D0 (no) Mikroelementenhet
BR9510586A (pt) Inflador
DE69734277D1 (de) Nullstromkreisunterbrechung
FR2721057B1 (fr) Chapiteau pliable et dépliable rapidement.
DE69535510D1 (de) Startverfahren und Einrichtung
KR960033565U (ko) 지압 및 쑥뜸 겸용 지압구
EP0873349A4 (en) Endothelial-monocyte activating polypeptide iii
FR2719067B1 (fr) Pavillon de loisir.
NO973370D0 (no) Redningsflåte
KR970028220U (ko) 판박이식 매니큐어